ESR1 and neoplasm: The estrogen receptor (ER) {Ventana} [Figure 2C] and progesterone receptor (PR) {Ventana} [Figure 2D] immunostains showed strong nuclear reactivity in 60–80% and 30–50% of tumor cells, respectively.